Navigation Links
St. Jude discovery offers new avenues to understanding an aggressive form of leukemia
Date:4/14/2008

Researchers at St. Jude Childrens Research Hospital have discovered evidence that a series of genetic mutations work together to initiate most cases of an aggressive and often-fatal form of acute lymphoblastic leukemia (ALL).

These defects, known as "cooperating oncogenic lesions," include the deletion of a gene, IKZF1, whose protein, Ikaros, normally helps guide the development of a blood stem cell into a lymphocyte. The researchers also found that loss of the same gene accompanied the transformation of chronic myelogenous leukemias (CMLs) to a life-threatening acute stage.

"These findings provide new avenues to pursue to gain a better understanding of these disease processes and, ultimately, to develop better therapies," said James R. Downing, M.D., St. Jude scientific director and chair of the Department of Pathology.

The new study, which he and his colleagues reported in the advance online publication of the journal "Nature," adds further support to a key concept in cancer genetics: Malignancies frequently require mutations in multiple genes in order to develop.

Cells contain oncogenes, which exist harmlessly until something triggers them to turn the cells malignant.

"It really takes a series of genetic lesions to lead to cancer," Downing said. "You may get activation of an oncogene, but you may also need activation of a tumor suppressor gene and an alteration in a cell-death pathway."

St. Jude researchers sought to identify genetic differences between CML and a form of acute leukemia known as BCR-ABL1{positive ALL.

Both diseases are characterized by the Philadelphia chromosome, which results from the translocation (joining) of parts of two different chromosomes. The result of this translocation is the expression of BCR-ABL1, an oncogene.

"It appears from our study, and other work published previously, that all you need to get CML is that chromosomal translocation and BCR-ABL1 expression," Downing said.

In their new study, the researchers re-examined the genetic makeup of 304 ALL patients who had been studied earlier. The group included 43 pediatric and adult BCR-ABL1 ALL patients and 23 adults with CML. Using a more sensitive technology, the scientists increased the number of genetic mutations found in their original gene survey.

In the first study, the gene most commonly altered was one called PAX5, followed by a gene designated IKZF1. Its protein, Ikaros, is involved in the development and differentiation of B lymphocyte cells, which are part of the immune system.

"The vast majority of pediatric acute lymphoblastic leukemias are of B-cell lineage," Downing said.

Among the ALL patients, the researchers found an average of 8.79 copy number alterations, a form of genetic change linked to the development and progression of cancer. The most common change was deletion of the gene for Ikaros.

The gene was deleted in 36 (83.7 percent) of the BCR-ABL1 ALL patients, including 76.2 percent of the pediatric and 90.9 percent of the adult cases.

"The loss of the Ikaros gene is a nearly obligatory lesion for the development of BCR-ABL1 ALL," Downing said, "and clearly must be a genetic lesion that is cooperating with BCR-ABL1."

Moreover, a gene known as CDKN2A was deleted in 53.5 percent of the BCR-ABL1 ALL patients, 87.5 percent of whom also had lost the gene for Ikaros. The PAX5 deletion occurred in 51 percent of the BCR-ABL1 ALL patients; and 95 percent of these people were missing the Ikaros gene.

Among the CML patients whose disease converted to ALL, two out of three had the deletion of the Ikaros gene; a lower percentage of those who converted to acute myeloblastic leukemia had the same gene deleted. That finding suggested that the deletion of Ikaros is cooperating with BCR-ABL1 to cause ALL.

"That is an important finding that may give insight into how that transformation occurs, or it may give insight into a better way to treat the disease, if one can figure out how the Ikaros deletion is working," Downing said.


'/>"/>

Contact: Carrie Strehlau
media@stjude.org
901-495-2295
St. Jude Children's Research Hospital
Source:Eurekalert

Related medicine news :

1. Jefferson scientists discovery may help explain smoking-pancreatic cancer link
2. Pollin Pediatric Research Prize awarded for discovery of lifesaving treatment of RDS
3. Mitosis gets harder thanks to new gene discovery
4. ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on Drug Commercialization
5. GeneGo Rolls out MetaMiner Cystic Fibrosis - the First Disease-Specific Software Platform to Advance Drug Discovery
6. Baby Madness is Sweeping the Nation! Forty Sets of Twins and Triplets Hit the Court in Discovery Healths BABY MADNESS: MULTIPLES
7. Novel discovery by Einstein scientists could lead to much-needed kidney failure treatment
8. New protein discovery helps researchers understand autoimmune diseases
9. Specialists in drug discovery and development convene
10. Keystone Programs for Collaborative Discovery Launch at Fox Chase
11. Natural Products Discovery and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... 27, 2017 , ... SyncDog, Inc. , the leading ... LG Business Solutions at ATARC Federal Mobile Computing Summit , March 28. ... education and examination into the mobility tools and technology employed by the Federal ...
(Date:3/27/2017)... ... March 27, 2017 , ... M&S Technologies, ... of Conformity for the Smart System® 20/20. CE Certification builds upon M&S's long-standing ... and specifications such as ANSI, ISO and proven test methods used in the ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... sideline athletes. A type of groin injury, it occurs when the muscles around ... intense pain in and around the lower torso, as well as accompanying tenderness ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek ... to pursue the recent RNA methylation “gold rush” with their established portfolio of ... newfound characteristics of N6-methyladenosine, or m6A , RNA methylation has received a ...
(Date:3/27/2017)... ... March 27, 2017 , ... Janet Schloz is still in shock after receiving a ... I’ve had in a long time,” she said. , She thinks the coming week is ... I never thought I would have to help my students.” , The award will allow ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... NASHUA, N.H. , March 27, 2017 /PRNewswire/ ... image analysis, workflow solutions and radiation therapy for ... announced that PowerLook® Tomo Detection received Premarket Approval ... (FDA). PowerLook Tomo Detection is a first-of-its-kind, concurrent-read ... tomosynthesis and is the latest innovation available on ...
(Date:3/27/2017)... March 27, 2017 Cota Healthcare, ... value-based precision medicine, today announced the signing ... Pharmaceuticals Corporation to help improve clinical and ... As part of this agreement, which ... entered into January 2016, teams from across ...
(Date:3/27/2017)... -- Invivotek, LLC, a Genesis Biotechnology Group ® ... contract research organization (CRO), announced the completion of the ... research facility in Hamilton, New Jersey ... source to reduce costs and lessen the CRO facility,s ... Farm follows Invivotek,s recent expansion from a 19,712 square ...
Breaking Medicine Technology: